The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.

MLA

Ma, Chanjuan, et al. “The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.” Cancer Immunology Research, vol. 7, no. 7, July 2019, pp. 1214–20. EBSCOhost, https://doi.org/10.1158/2326-6066.CIR-18-0613.

APA

Ma, C., Hodi, F. S., Giobbie-Hurder, A., Wang, X., Zhou, J., Zhang, A., Zhou, Y., Mao, F., Angell, T. E., Andrews, C. P., Hu, J., Barroso-Sousa, R., Kaiser, U. B., Tolaney, S. M., & Min, L. (2019). The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. Cancer Immunology Research, 7(7), 1214–1220. https://doi.org/10.1158/2326-6066.CIR-18-0613

Chicago

Ma, Chanjuan, F Stephen Hodi, Anita Giobbie-Hurder, Xiaocheng Wang, Jing Zhou, Amy Zhang, Ying Zhou, et al. 2019. “The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.” Cancer Immunology Research 7 (7): 1214–20. doi:10.1158/2326-6066.CIR-18-0613.